查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1671092

全球重症肌无力市场：市场规模、占有率、趋势、产业分析（依治疗类型、最终用途和地区）、未来预测（2025-2034）

Global Myasthenia Gravis Disease Market Size, Share, Trends, Industry Analysis Report: By Treatment Type, End Use, and Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，重症肌无力疾病市场预计到2034年将达到 61.9亿美元。本报告深入了解了当前的市场动态，并对未来的市场成长进行了分析。

重症肌无力（MG）是一种慢性自体免疫疾病，导致骨骼肌无力，尤其是控制眼球、脸部肌肉和四肢自主运动的骨骼肌无力。当人体免疫系统产生抗体，干扰神经细胞和肌肉细胞之间的通讯，阻止讯号的正常传输时，就会发生这种疾病。

重症肌无力疾病市场受到多种因素的推动，包括全球盛行率的增加、诊断技术的进步以及对更有效治疗方案的需求不断成长。单株抗体和免疫疗法等生物製剂的开发和批准为患者提供了治疗严重重症肌无力的新方法。

此外，根据基因和分子特征制定治疗方案的个人化医疗趋势也备受关注。重症肌无力疾病市场的成长也得益于患者意识的提高、临床试验的扩大以及医疗保健机会的改善，尤其是在亚太地区等新兴市场。机会包括满足难以治疗的患者的需求、提高医疗费用的可负担性以及扩大获得先进疗法的机会。总体而言，随着更有效、更容易取得的治疗方案不断涌现，市场预计将稳定成长。

重症肌无力疾病市场：概论

胆碱酯酶抑制剂在重症肌无力市场中占据主导地位，是大多数轻度至中度症状患者的主要治疗方法。然而，由于对重症病例的晚期治疗的需求不断增加，包括 IVIG 和血浆置换在内的快速免疫治疗领域正显示出最快的成长。

在重症肌无力疾病市场中，医院占据最大的市场占有率，因为它们提供从急性发作到重症的综合治疗。然而，由于越来越多的人转向门诊护理以及获得专科护理的机会增加，诊所部门经历最快的成长。

由于先进的医疗基础设施、高度的认知度和庞大的患者数量，北美在重症肌无力市场中占据主导地位。然而，由于医疗保健管道的扩大、诊断能力的提高以及创新疗法的采用不断增加，亚太地区是成长最快的市场。

目录

第1章 简介

第2章 执行摘要

第3章 分析方法

第4章 重症肌无力疾病市场洞察

  • 市场概况
  • 重症肌无力疾病的市场动态
    • 驱动因素和机会
      • 越来越重视标靶治疗
      • 免疫疗法的进展
    • 阻碍因素和挑战
      • 存活率低
  • PESTLE 分析
  • 重症肌无力疾病市场的趋势
  • 价值链分析
  • COVID-19 影响分析

第5章 全球重症肌无力疾病市场（依治疗类型）

  • 主要调查结果
  • 简介
  • 胸腺切除术
  • 胆碱酯酶抑制剂
  • 快速免疫疗法

第6章 全球重症肌无力疾病市场（依最终用途）

  • 主要调查结果
  • 简介
  • 科学研究
  • 药物与疫苗的研究与开发
  • 克隆实验
  • 其他

第7章 全球重症肌无力疾病市场（依地区）

  • 主要调查结果
  • 简介
    • 依地区对重症肌无力疾病市场的评估（2020-2034年）
  • 北美洲
    • 北美：依治疗类型（2020-2034年）
    • 北美：依最终用途（2020-2034年）
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲：依治疗类型（2020-2034年）
    • 欧洲：依最终用途（2020-2034年）
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
    • 其他欧洲国家
  • 亚太地区
    • 亚太地区：依治疗类型（2020-2034年）
    • 亚太地区：依最终用途（2020-2034年）
    • 中国
    • 印度
    • 马来西亚
    • 日本
    • 印尼
    • 韩国
    • 澳洲
    • 其他亚太地区
  • 中东和非洲
    • 中东和非洲：依治疗类型（2020-2034年）
    • 中东和非洲：依最终用途（2020-2034年）
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
    • 其他中东和非洲地区
  • 拉丁美洲
    • 拉丁美洲：依治疗类型（2020-2034年）
    • 拉丁美洲：依最终用途（2020-2034年）
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他拉丁美洲国家

第8章 竞争格局

  • 扩张与收购分析
    • 扩张
    • 收购
  • 伙伴关係/协作/协议/公开

第9章 公司简介

  • Alexion Pharmaceuticals（AstraZeneca）
  • Mitsubishi Tanabe Pharma
  • Bristol Myers Squibb
  • Grifols
  • Baxter International
  • CSL Behring
  • UCB
  • Prothena Biosciences
  • Argenx
  • Sanofi
  • Amgen
  • AbbVie
  • Pfizer
  • Roche
  • Novartis
Product Code: PM1546

The myasthenia gravis disease market size is expected to reach USD 6.19 billion by 2034, according to a new study by Polaris Market Research. The report "Myasthenia Gravis Disease Market Size, Share, Trends, Industry Analysis Report: By Treatment Type (Thymectomy, Cholinesterase Inhibitors, and Rapid Immunotherapies), End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Myasthenia Gravis (MG) is a chronic autoimmune disorder that causes weakness in the skeletal muscles, particularly those responsible for controlling voluntary movements like eye muscles, facial muscles, and limbs. The condition occurs when the body's immune system produces antibodies that interfere with the communication between nerve cells and muscle cells, preventing the normal transmission of signals.

The myasthenia gravis disease market is driven by several factors, including the increasing global prevalence of the condition, advancements in diagnostic techniques, and the growing demand for more effective treatment options. The development and approval of biologic therapies, such as monoclonal antibodies and immunotherapies, are offering patients new ways to manage severe forms of the disease.

Additionally, the trend toward personalized medicine, which tailors treatments based on genetic and molecular profiles, is gaining traction. The myasthenia gravis disease market growth is also supported by rising patient awareness, the expansion of clinical trials, and improving healthcare access, particularly in emerging markets such as Asia Pacific. Opportunities lie in addressing the needs of refractory patients, improving treatment affordability, and expanding access to advanced therapies. Overall, the market is poised for steady growth as more effective and accessible treatment options continue to emerge.

Myasthenia Gravis Disease Market Report Highlights

Cholinesterase inhibitors dominate the myasthenia gravis market, serving as the primary treatment for most patients with mild to moderate symptoms. However, the segment of rapid immunotherapies, including IVIG and plasmapheresis, is registering the fastest growth due to increasing demand for advanced therapies in severe cases.

Hospitals hold the largest myasthenia gravis disease market share in the myasthenia gravis treatment market, as they provide comprehensive care for both acute exacerbations and severe MG cases. The clinic segment, however, is experiencing the fastest growth, driven by the increasing shift towards outpatient care and improved accessibility to specialized treatments.

North America dominates the myasthenia gravis market, owing to its advanced healthcare infrastructure, high awareness, and significant patient population. However, Asia Pacific is the fastest growing market, driven by expanding healthcare access, improving diagnostic capabilities, and increasing adoption of innovative therapies.

Polaris Market Research has segmented the myasthenia gravis disease market report based on treatment type, end-use, and region:

By Treatment Type Outlook (Revenue-USD Billion, 2020 - 2034)

  • Thymectomy
  • Cholinesterase Inhibitors
  • Rapid Immunotherapies

By End Use Outlook (Revenue-USD Billion, 2020 - 2034)

  • Hospitals
  • Clinics

By Regional Outlook (Revenue-USD Billion, 2020 - 2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Myasthenia Gravis Disease Market Insights

  • 4.1. Myasthenia Gravis Disease Market - Market Snapshot
  • 4.2. Myasthenia Gravis Disease Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increased Focus on Targeted Therapies
      • 4.2.1.2. Advancements in Immunotherapy
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Low Survival Rates
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Myasthenia Gravis Disease Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Myasthenia Gravis Disease Market, by Treatment Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • 5.3. Thymectomy
    • 5.3.1. Global Myasthenia Gravis Disease Market, by Thymectomy, by Region, 2020-2034 (USD Billion)
  • 5.4. Cholinesterase Inhibitors
    • 5.4.1. Global Myasthenia Gravis Disease Market, by Cholinesterase Inhibitors, by Region, 2020-2034 (USD Billion)
  • 5.5. Rapid Immunotherapies
    • 5.5.1. Global Myasthenia Gravis Disease Market, by Rapid Immunotherapies, by Region, 2020-2034 (USD Billion)

6. Global Myasthenia Gravis Disease Market, by End-use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • 6.3. Scientific Research
    • 6.3.1. Global Myasthenia Gravis Disease Market, by Scientific Research, by Region, 2020-2034 (USD Billion)
  • 6.4. Medicine and Vaccine R&D
    • 6.4.1. Global Myasthenia Gravis Disease Market, by Medicine and Vaccine R&D, by Region, 2020-2034 (USD Billion)
  • 6.5. Cloning Experiment
    • 6.5.1. Global Myasthenia Gravis Disease Market, by Cloning Experiment, by Region, 2020-2034 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Myasthenia Gravis Disease Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Myasthenia Gravis Disease Market, by Geography

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Myasthenia Gravis Disease Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 7.3. Myasthenia Gravis Disease Market - North America
    • 7.3.1. North America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
    • 7.3.2. North America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.3.3. Myasthenia Gravis Disease Market - U.S.
      • 7.3.3.1. U.S.: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.3.3.2. U.S.: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.3.4. Myasthenia Gravis Disease Market - Canada
      • 7.3.4.1. Canada: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.3.4.2. Canada: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • 7.4. Myasthenia Gravis Disease Market - Europe
    • 7.4.1. Europe: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
    • 7.4.2. Europe: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.3. Myasthenia Gravis Disease Market - UK
      • 7.4.3.1. UK: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.3.2. UK: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.4. Myasthenia Gravis Disease Market - France
      • 7.4.4.1. France: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.4.2. France: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.5. Myasthenia Gravis Disease Market - Germany
      • 7.4.5.1. Germany: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.5.2. Germany: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.6. Myasthenia Gravis Disease Market - Italy
      • 7.4.6.1. Italy: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.6.2. Italy: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.7. Myasthenia Gravis Disease Market - Spain
      • 7.4.7.1. Spain: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.7.2. Spain: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.8. Myasthenia Gravis Disease Market - Netherlands
      • 7.4.8.1. Netherlands: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.8.2. Netherlands: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.9. Myasthenia Gravis Disease Market - Russia
      • 7.4.9.1. Russia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.9.2. Russia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.10. Myasthenia Gravis Disease Market - Rest of Europe
      • 7.4.10.1. Rest of Europe: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.10.2. Rest of Europe: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • 7.5. Myasthenia Gravis Disease Market - Asia Pacific
    • 7.5.1. Asia Pacific: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
    • 7.5.2. Asia Pacific: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.3. Myasthenia Gravis Disease Market - China
      • 7.5.3.1. China: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.3.2. China: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.4. Myasthenia Gravis Disease Market - India
      • 7.5.4.1. India: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.4.2. India: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.5. Myasthenia Gravis Disease Market - Malaysia
      • 7.5.5.1. Malaysia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.5.2. Malaysia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.6. Myasthenia Gravis Disease Market - Japan
      • 7.5.6.1. Japan: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.6.2. Japan: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.7. Myasthenia Gravis Disease Market - Indonesia
      • 7.5.7.1. Indonesia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.7.2. Indonesia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.8. Myasthenia Gravis Disease Market - South Korea
      • 7.5.8.1. South Korea: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.8.2. South Korea: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.9. Myasthenia Gravis Disease Market - Australia
      • 7.5.9.1. Australia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.9.2. Australia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.10. Myasthenia Gravis Disease Market - Rest of Asia Pacific
      • 7.5.10.1. Rest of Asia Pacific: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.10.2. Rest of Asia Pacific: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • 7.6. Myasthenia Gravis Disease Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
    • 7.6.2. Middle East & Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.6.3. Myasthenia Gravis Disease Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.6.4. Myasthenia Gravis Disease Market - UAE
      • 7.6.4.1. UAE: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.6.4.2. UAE: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.6.5. Myasthenia Gravis Disease Market - Israel
      • 7.6.5.1. Israel: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.6.5.2. Israel: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.6.6. Myasthenia Gravis Disease Market - South Africa
      • 7.6.6.1. South Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.6.6.2. South Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.6.7. Myasthenia Gravis Disease Market - Rest of Middle East & Africa
      • 7.6.7.1. Rest of Middle East & Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.6.7.2. Rest of Middle East & Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • 7.7. Myasthenia Gravis Disease Market - Latin America
    • 7.7.1. Latin America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
    • 7.7.2. Latin America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.7.3. Myasthenia Gravis Disease Market - Mexico
      • 7.7.3.1. Mexico: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.7.3.2. Mexico: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.7.4. Myasthenia Gravis Disease Market - Brazil
      • 7.7.4.1. Brazil: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.7.4.2. Brazil: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.7.5. Myasthenia Gravis Disease Market - Argentina
      • 7.7.5.1. Argentina: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.7.5.2. Argentina: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.7.6. Myasthenia Gravis Disease Market - Rest of Latin America
      • 7.7.6.1. Rest of Latin America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.7.6.2. Rest of Latin America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Alexion Pharmaceuticals (AstraZeneca)
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Mitsubishi Tanabe Pharma
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Bristol Myers Squibb
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Grifols
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Baxter International
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. CSL Behring
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. UCB
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Prothena Biosciences
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Argenx
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Sanofi
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Amgen
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. AbbVie
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Pfizer
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Roche
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Novartis
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development

List of Tables:

  • Table 1 Global Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 2 Global Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 3 North America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 4 North America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 5 U.S.: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 6 U.S.: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 7 Canada: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 8 Canada: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 9 Europe: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 10 Europe: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 11 UK: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 12 UK: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 13 France: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 14 France: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 15 Germany: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 16 Germany: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 17 Italy: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 18 Italy: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 19 Spain: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 20 Spain: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 21 Netherlands: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 22 Netherlands: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 23 Russia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 24 Russia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 25 Rest of Europe: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 26 Rest of Europe: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 27 Asia Pacific: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 28 Asia Pacific: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 29 China: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 30 China: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 31 India: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 32 India: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 33 Malaysia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 34 Malaysia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 35 Japan: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 36 Japan: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 37 Indonesia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 38 Indonesia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 39 South Korea: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 40 South Korea: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 41 Australia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 42 Australia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 43 Rest of Asia Pacific: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 44 Rest of Asia Pacific: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 45 Middle East & Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 46 Middle East & Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 47 Saudi Arabia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 48 Saudi Arabia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 49 UAE: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 50 UAE: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 51 Israel: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 52 Israel: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 53 South Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 54 South Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 55 Rest of Middle East & Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 56 Rest of Middle East & Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 57 Latin America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 58 Latin America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 59 Mexico: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 60 Mexico: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 61 Brazil: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 62 Brazil: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 63 Argentina: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 64 Argentina: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 65 Rest of Latin America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 66 Rest of Latin America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Myasthenia Gravis Disease Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment Type
  • Figure 7. Global Myasthenia Gravis Disease Market, by Treatment Type, 2024 & 2034 (USD Billion)
  • Figure 8. Market by End-use
  • Figure 9. Global Myasthenia Gravis Disease Market, by End-use, 2024 & 2034 (USD Billion)